Acetylon has developed a pipeline of optimized, orally administered, HDAC6 isoform selective compounds representing several, chemically distinct and separately patentable chemical “scaffolds” or families.  Acetylon’s first clinical candidate, the selective HDAC6 inhibitor “ACY-1215,” is targeted for the treatment of hematologic and solid tumor cancers and is currently being entered into US Phase I clinical testing for the treatment of multiple myeloma. Acetylon is also exploring in preclinical studies several additional potential cancer indications, including certain leukemias, lymphomas and solid tumors, where selective inhibition of HDAC6 is anticipated by Acetylon to potentially provide a favorable anti-cancer effect as a single agent and/or in combination with existing anti-cancer agents including proteasome inhibitors, immunomodulatory agents, and others.